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How do infections trigger or aggravate renal pathology?
The discovery of the toll-like receptors, and more recently,
the retinoic-acid-inducible protein-like helicases and the
nucleotide-binding oligomerization domain-like receptors
may offer new concepts to answer this question. Common
pathogen-associated molecules are recognized by these
receptors in several cellular compartments of immune cells
and non-immune cells inside the kidney. This article
summarizes ligand–receptor interactions and their known or
potential significance in kidney diseases.
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Infections cause many types of kidney diseases, directly or
indirectly, and in both disease entities, host defense involves
immunity-mediated pathology. What are the molecular
mechanisms that mediate pathogen recognition and im-
munity-related renal damage? Why do some but not all
microbes trigger immunity? Is pathogen recognition re-
stricted to immune cells or do renal cells also contribute to
this phenomenon? Which molecules recognize different
classes of pathogens like bacteria or viruses and what is the
evidence that single pathogen recognition molecules have a
crucial role in distinct types of kidney disease?
The understanding of innate pathogen recognition has
been stimulated by the discovery of the human toll-like
receptor (TLR) family 13 years ago. Since 2004 when we first
reviewed the potential roles of TLRs in kidney disease, the
evolving data propose novel disease concepts. Furthermore,
the subsequent discovery of the nucleotide-binding oligo-
merization domain (NOD)-like receptor (NLR) family and
the retinoic-acid-inducible protein (RIG)-like helicases
(RLH) has broadened the view of how innate immunity
assures pathogen recognition in different cellular compart-
ments.1 This review provides an update on the role of the
recognition of pathogen-associated molecules in kidney
diseases and discusses future perspectives in this field.
BACTERIAL WALL COMPONENTS
A group of cell surface TLRs and cytosolic NLRs recognize
bacterial cell wall components (Table 1). A major cell wall
component of all bacteria is peptidoglycan (PG), whereas
lipoproteins and lipoteichoic acid are specific to Gram-
positive bacteria, and lipopolysaccharide (LPS) is specific for
Gram-negative bacteria.
LPS–TLR4: The lipid core of LPS is a potent immunos-
timulatory cell wall component of Gram-negative bacteria.
The LPS and soluble LPS-binding protein complex exposes
LPS to CD14, MD-2 and the extracellular domain of TLR4 at
the outer cell membrane.2 Most cell types express TLR4 and
respond to LPS. Outside-in signaling recruits cytosolic
adapter molecules, which interact with their toll-interleukin 1
receptor (TIR) domain with the intracellular TIR domain of
TLR4.3 TLR4 can activate both the myeloid differentiation
primary-response protein (MyD)-88- (tumor necrosis factor
receptor associated factor (TRAF)-6, IL-1 receptor-associated
kinase-1, interferon regulatory factor (IRF)-5, nuclear factor-
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kB (NF-kB)) and the TIR domain-containing adaptor
protein-inducing-interferon-b- (TRAF-6-, IRF-3-, and NF-kB-)
dependent-signaling pathways (Figure 1).3 Hence, bacterial
LPS is a potent inducer of proinflammatory cytokines and
type I interferons (IFNs).
PG/lipoproteins/lipoteichoic acid–TLR1/2 or TLR2/6: TLR2
homo- or heterodimerization at the cell surface allows to
detect numerous ligands. TLR2 homodimers recognize PG, a
constitutive bacterial cell wall component of all bacteria.2
TLR1-TLR2 heterodimers recognize triacyl lipopeptides
present in the cell wall of Gram-positive bacteria and
mycobacteria and TLR2-TLR6 heterodimers recognize diacyl
lipopeptides and lipoteichoic acid.2 The intracellular signal-
ing of TLR1, TLR2, and TLR6 depends on the MyD88-
signaling pathway (Figure 1).
PG–NOD: the cytosolic NLRs detect bacteria that have
entered the intracellular cytosol.2 NOD1 and NOD2
recognize bacterial PG. Diaminopimelic acid, a structural
component of PG, ligates NOD1 and muramyldipeptide is a
ligand for NOD2.4 Ligand binding to NOD1 and NOD2
causes their oligomerization and results in NF-kB activation
by recruiting receptor-interacting protein/receptor interact-
ing protein-like interacting CLARP kinase, a serine/threonine
kinase, to their caspase-recruiting domain by homophilic
interactions. NOD1- or NOD2-deficient macrophages fail to
produce cytokines in response to bacterial PG.
Bacterial cell wall recognition in kidney disease
Infections outside the kidney. Extrarenal bacterial infections
release bacterial cell wall components into the circulation. For
example, LPS exposure triggers systemic cytokine release,
renal failure, and eventually fatal septic shock via extrarenal
TLR4-MyD88 signaling.5 TLR4 mutant C3H/HeJ mice do
not respond to LPS challenge. Consistent with this observa-
tion, patients with loss-of-function mutations in the TLR4
gene are more susceptible to infections with Gram-negative
bacteria due to inadequate pathogen control by the innate
immune system.6 Accordingly, patients with defective TLR2
signaling are more susceptible to staphylococcal septic
shock.6 Systemic exposure to TLR2 and TLR4 ligands can
also aggravate other types of kidney diseases, for example
nephrotoxic serum nephritis, by enhanced production of
antibodies and T cells specific for glomerular antigens.7
Furthermore, bacterial cell wall components elicit intrarenal
cytokine release via TLR2 and TLR4 on intrinsic glomerular
cells and tubular epithelial cells.7–10 Podocytes express TLR4
and undergo dedifferentiation after LPS challenge.8 TLR4 is
also expressed at the brush border of proximal tubular
epithelial cells.11 However, the expression and function of
most TLRs, RLHs, and NLRs on intrinsic renal cells needs to
be better characterized in the future. Interestingly, renal TLR2
is involved in renal ischemia-reperfusion injury suggesting
that endogenous ligands to these receptors exist and that
these contribute to the pathogenesis of non-infectious types
of kidney diseases.12
Renal infections. In infective pyelonephritis tubular cells
and the intrarenal network of myeloid cells both contribute
to innate pathogen recognition and host defense. Lack of
TLR4 in either cell type impairs host defense against
uropathogenic Escherichia coli.13 By contrast, leptospira is
Table 1 | Pathogen-associated molecules and innate pathogen recognition receptors
Pathogen component Molecular pattern Toll-like receptor RIG-like helicase NOD-like receptor
Bacterial wall
All bacteria Peptidoglycan TLR2 NOD1, NOD2
Gram bacteria Lipopolysaccharide TLR4
Gram+ bacteria Triacyl lipopeptides TLR1-TLR2
Lipoteichoic acid TLR2-TLR6
Diacyl lipopeptides TLR2-TLR6
Porins TLR2
Mycobacteria Lipoarabinomannan TLR2
Triacyl lipopeptides TLR1-TLR2
Microbial or viral nucleic acids
DNA CpG-DNA TLR9
dsDNA — ?
RNA dsRNA TLR3 MDA5, RIG-I
ssRNA TLR7, TLR8
3P-RNA RIG-I
Other pathogen components
Flagella Flagellin TLR5 NAIP5, IPAF
Uropathogenic E. coli ? mTLR11
Viral envelope proteins RSV envelope protein TLR4
Measle virus hemagglutinin TLR2
CMV, HSV1 proteins TLR2
Fungal cell wall Candida phospholipomannan TLR2
Candida mannan TLR4
Saccharomyces zymosan TLR2/TLR6
CMV, cytomegalovirus; NOD, nucleotide-binding oligomerization domain; 3P-RNA, 50-triphosphate RNA; RIG, retinoic-acid-inducible protein; TLR, toll-like receptor.
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recognized by TLR2.14 The network of interstitial myeloid
dendritic cells and tubular epithelial cells both express TLR1-
6 and express chemokines upon exposure to Escherichia coli
LPS.15 Interestingly, the regulation of their TLR signaling is
different. Intrarenal dendritic cells, but not tubular epithelial
cells, express functional TIR8/single immunoglobulin IL-1
receptor-related molecule, an orphan receptor of interleukin-1
(IL-1)/TLR family with suppressive functions on TLR
signalling (Figure 1). However, the significance of defective
TLR2 or TLR4 signaling on urinary tract infections in
humans is yet poorly evaluated. One may speculate that
TLR2 or TLR4 mutations may increase the prevalence of
asymptomatic bacteriuria or urosepsis due to a lack of local
pathogen control.
OTHER BACTERIAL COMPONENTS
Flagellin–TLR5: the constant D295 and D367 domains of
flagellin, an integral component of bacterial flagella, ligates
TLR5 on the cell surface and activates antigen-presenting
cells to mature and to secrete proinflammatory mediators.2
Furthermore, TLR5 is expressed at the basolateral membrane
of epithelial cells of the gut and lung, for example, faci-
litating the selective recognition of invasive bacterial gro-
wth and ignoring commensal bacteria. TLR5 signaling
depends on the MyD88-signaling pathway and involves
TRAF-6, IL-1 receptor-associated kinase-4, IRF-5, and NF-kB
(Figure 1).3
Flagellin–neuronal apoptosis inhibitory protein 5/ICE
protease activating factor: TLR5-independent recognition of
flagellin in the cytosol is mediated by members of the NOD-
LRR protein family, neuronal apoptosis inhibitory protein 5
and ICE protease activating factor.2
Uropathogenic Escherichia coli–TLR11: TLR11 was found to
mediate cytokine release upon exposure to uropathogenic
Escherichia coli in a MyD88-dependent manner. TLR11 is
expressed in macrophages and in epithelial cells of the kidney
and the urinary bladder in mice. Renal TLR11 signaling has a
protective role in Escherichia coli pyelonephritis in mice but
not in humans as humans lack functional TLR11.2
Flagellin recognition in kidney disease
TLR5 signaling is required for neutrophil recruitment upon
inoculation of Escherichia coli into the urinary bladder in
mice.16 Whether this mechanism applies to human urinary
tract infection is unknown, but humans require functional
TLR5 for defense against Legionella pneumophila.17
BACTERIAL AND VIRAL DNA
DNA serves as a universal pathogen-associated molecular
pattern. DNAses rapidly digest extracellular DNA, hence,
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Figure 1 | TLRs, RLHs, and NLRs in renal cells. Intrinsic renal non-immune cells express a restricted TLR pattern as compared with intrarenal
myeloid dendritic cells (and macrophages). Whether RLHs and NLRs are expressed by both types of renal cells has not yet been characterized in
detail. TLRs signal through the MyD88 and/or TIR domain-containing adaptor protein-inducing-interferon-b-signaling pathways for the
induction of proinflammatory cytokines and type I IFNs. The RLHs signal through mitochondrial interferon-b promoter stimulator-1 and NLR
use receptor-interacting protein-like interacting CLARP kinase. The respective ligands to these receptors are indicated in red (LPS,
lipopolysaccharide; PG, peptidoglycan; LTA, lipoteichoic acid; LP, lipoprotein; 3P-RNA, 50-triphosphate RNA).
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innate DNA receptors do only occur in intracellular
endosomes and the cytosol (Table 1). No DNA receptors
are known inside the nucleus, which assures tolerance to self-
DNA but which may represent a niche for certain DNA
viruses. Two DNA formats elicit immunostimulatory effects
(Table 2).
Cytosin-guanosine (CpG) DNA–TLR9: the CpG dinucleo-
tide represents the immunostimulatory motif of bacterial and
viral DNA, which ligates TLR9.2 TLR9 resides in intracellular
endosomes of the endoplasmic reticulum, which fuse with
endolysosomes for the recognition of bacterial or viral DNA
only after phagocytic uptake of the pathogen and after lysis of
its wall or envelope structures. Extracellular microbial or self-
DNA can escape DNAse digestion and trigger TLR9 signaling
when being complexed with other proteins, for example
high-mobility group box 1 protein, malarial hemozoin, or
immune complexes.18 TLR9 signaling depends on the
MyD88, TRAF-6, IL-1 receptor-associated kinase-1, IRF-7,
and NF-kB (Figure 1).3 Only plasmacytoid dendritic cells and
B cells express TLR9. CpG DNA activates plasmacytoid
dendritic cells to maturate, to secrete Th1 cytokines for CD8
T-cell priming, and to secrete type 1 IFNs. Furthermore, CpG
DNA activates B-cell proliferation and antibody production.
dsDNA–cytosolic DNA receptors: viral dsDNA triggers
cytokine release when delivered into the cytosol,2 but the
cytosolic DNA receptor(s) are yet unknown. Immune and
non-immune cells respond to cytosolic dsDNA, which
involves the noncanonical IkB kinase TANK-binding ki-
nase-1 and NF-kB-independent activation of mitogen-
activated protein kinases (Figure 1).2 This mechanism allows
to recognize DNA viruses that deliver their DNA directly into
the cytosol potentially in any cell type and to generate a first
tissue-based proinflammatory signal to be further enhanced
by professional IFN-producing cells.
DNA recognition in kidney disease
Infections outside the kidney. Acute or chronic infections with
DNA viruses are common, for example, human herpes
viruses, Ebstein–Barr virus, adenoviruses, or polyomaviruses;
and are commonly associated with renal pathology. Experi-
mentally, systemic exposure to CpG DNA has a unique role in
triggering the onset of lupus nephritis in autoimmune-prone
MRLlpr/lpr but not in MRL wild-type mice.19 This is because
CpG-DNA increases serum cytokine levels, B-cell prolifera-
tion, and autoantibody production in these mice. Similar
mechanisms operate when a transient exposure to CpG DNA
aggravates a preexisting glomerulonephritis.19 Does TLR-
independent cytosolic recognition of dsDNA has similar
effects? We observed that systemic exposure of complexed
double-stranded non-CpG DNA enhances lymphoprolifera-
tion, autoantibody production, and glomerulonephritis in
nephritic mice (unpublished observation). This may involve
local immunostimulatory effects, because the dsDNA was
found to localize to the cytosol of glomerular and tubular
epithelial cells in affected mice after intravenous injection.
Renal infections. Cytomegalovirus or polyomavirus com-
monly cause renal allograft nephropathy in which the viruses
replicate in tubular epithelial cells. TLR9 was shown to
mediate cytomegalovirus-induced activation of dendritic
cells,20 but MyD88-independent recognition of cytomegalo-
virus also exists. Cytomegalovirus or polyomavirus do also
infect tubular epithelial cells but whether viral DNA can
activate innate defense mechanisms in tubular epithelial cells,
which lack TLR9 expression remains to be studied.
VIRAL RNA
The immunostimulatory effects of viral RNA refer to three
distinct RNA formats, that is dsRNA via TLR3 or via
melanoma-differentiation-associated gene (MDA)5 and via
RIG-I, U-rich ssRNA via TLR7/8, and 50-triphosphate RNA
(3P-RNA) via RIG-I (Table 3).2 Self-RNA is usually ignored
by these receptors because (a) RNAses rapidly digest
extracellular RNA, (b) self-RNA rarely reaches intracellular
endosomes, (c) self-RNA is mostly methylated, and (d) in
self-RNA the stimulatory 50-triphosphate motif is capped or
modified during post-transcriptional RNA processing.
dsRNA–TLR3: TLR3 recognizes genomic viral dsRNA or
RNA intermediates generated during viral replication, all
of which were shown to trigger antiviral immunity. TLR3
resides in intracellular endosomes that fuse with endolyso-
somes after phagocytic uptake of viral particles and break-
down of their envelope structures. TLR3 signaling depends
on the TIR domain-containing adaptor protein-inducing-
interferon-b, TRAF-6, IRF-3, and NF-kB-signaling pathway
(Figure 1).3 The interaction of dsRNA with TLR3 is a potent
inducer of type I IFNs, the maturation of myeloid dendritic
cells and for inducing adaptive T-cell responses. TLR3 is the
only nucleic acid-specific TLR, which is expressed in non-
immune cells types like fibroblasts, endothelial cells,
mesangial cells, and tubular epithelial cells.9,10 Viral dsRNA
cannot activate B cells as they lack TLR3 expression.
However, TLR3 is a crucial mediator in the antiviral
defense, for example against cytomegalovirus or West Nile
virus.20,21 Self-RNAs were also shown to activate dendritic
Table 2 | Innate DNA recognition
TLR-dependent TLR-independent
DNA format CpG-DNA dsDNA
Self vs. non-self
distinction
methylation (self) ?
Cellular compartment endosomes Cytosol
Receptor TLR9 ?
Signaling molecules MyD88, TRAF-6,
IRAK-1, IRF-7, NF-kB
TBK-1, IRF-3
Cell type-specific
expression
plasmacytoid
dendritic cells, B cells,
macrophages (mice)
Dendritic cells, B
cells, fibroblasts,
mesangial cells,
tubular epithelial
cells (all non-immune
cells?)
MyD88, myeloid differentiation primary-response protein 88; IRAK-1, interleukin-1
receptor-associated kinase-1; IRF-7, interferon regulatory factor-7; NF-kB, nuclear
factor-kB; TBK-1, TANK-binding kinase-1; TLR, toll-like receptor; TRAF-6, tumor
necrosis factor receptor associated factor.
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cells via TLR3, but whether this finding plays a role in vivo is
unclear.
dsRNA–MDA5/RIG-I: viral dsRNA can still stimulate
TLR3-deficient dendritic cells, especially, when transfected
directly into the cytosol.2 The RLHs MDA5 and RIG-I were
recently identified to be the cytosolic viral RNA receptors
(Table 3). Upon cytosolic transfection viral dsRNA induce
type-I IFN production and dendritic cell activation via
MDA5 and RIG-I, mitochondrial interferon-b promoter
stimulator-1, and the noncanonical IkB kinase TANK-
binding kinase-1.2 To date, it remains unclear how cytosolic
self-RNAs, for example tRNA, rRNA, or mRNA, are
protected from activating MDA5 and RIG-I.
ssRNA–TLR7/8: genomic viral ssRNA or ssRNA inter-
mediates ligate TLR7 and hTLR8 in intracellular endosomes
and trigger antiviral immunity via the MyD88, TRAF-6, IL-1
receptor-associated kinase-1, IRF-7, and NF-kB (Figure 1).2,3
TLR7 signaling is restricted to plasmacytoid dendritic cells
and B cells in humans and activates dendritic cell maturation,
to secrete Th1 cytokines for CD8 T cell priming, and to
secrete type I IFNs. Type I IFNs amplify TLR7 signaling in an
autocrine loop, which fosters proliferation and antibody
production in B cells. TLR8 is expressed in human
monocytes and can enhance the production of proinflam-
matory cytokines, especially, IL-12. These effects integrate to
a potent antiviral immune response, which can be mimicked
for therapeutic use. The TLR7 agonist imiquimod (5%
cream) is used to treat external genital warts, basal cell
carcinoma, and actinic keratosis, and is in clinical trials
against human papillomavirus.22
Self-RNA may eventually trigger TLR7 signaling when
RNA-containing immune complexes are internalized via the
B-cell receptor into intracellular endosomes of B cells or via
Fc receptors into dendritic cells and macrophages.18 For
example, lupus immune complexes containing U1 small
nuclear ribonuclear protein RNA specifically ligate TLR7 in
plasmacytoid dendritic cells.18 The importance of TLR7 in
the pathogenesis of lupus nephritis was recently documented
by studies with lupus-prone TLR7-deficient MRLlpr/lpr mice,
TLR7-overexpressing mice,18 and in nephritic MRLlpr/lpr mice
treated with a TLR7 antagonist.23
50-triphosphate RNA–RIG-1: RIG-I is a cytosolic receptor
for viral 50-triphosphate RNA, a characteristic of many viral
ssRNAs (Table 3).24 RIG-I and MDA5 share the same
signaling pathway (Figure 1).3 The cell type-specific expres-
sion of RIG-I is less clear but TLR-independent recognition
of ssRNA is a feature of many immune and non-immune cell
types including mesangial cells.
RNA recognition in kidney disease
Infections outside the kidney. RNA virus infections, like with
hepatitis C virus, release viral RNA–protein complexes into
the circulation, which reach or precipitate in the glomerular
mesangium, a condition often associated with glomerulone-
phritis. TLR3 mRNA is specifically induced in hepatitis C
glomerulonephritis but not in non-HCV glomerulonephri-
tis.25 In fact, viral dsRNA localizes to intracellular endosomes
of mesangial cells after injection fostering local production of
IL-1, IL-6, IL-8, monocyte chemotactic protein-1/CCL2,
regulated on activation, normally T-cell expressed and
secreted/CCL5.19,25 Furthermore, the antiproliferative and
proapoptotic effect of viral dsRNA on cultured mesangial
cells is consistent with mesangiolytic lesions of nephritic mice
repeatedly challenged with viral dsRNA injections.19 In
mesangial cells, cytokines like IFN-g and tumor necrosis
factor upregulate TLR3 and enhance TLR3 signaling.10,25 The
cell type-specific expression of TLR3 and TLR7/8 determine
the different TLR-mediated biological effects of viral dsRNA
and ssRNA. In contrast to TLR3, TLR7 is absent on non-
immune cells but present on B cells. Hence, systemic
exposure to TLR7 agonists triggers antibody production
and glomerular immune complex deposits in immune
complex glomerulonephritis but lacks the activation of
intrinsic renal cells.19 However, both TLRs can activate
intrarenal immune cells such as macrophage infiltrates
present in glomerulonephritis. TLR3 and TLR7 co-activation
can have synergistic effects on the activation of dendritic cells
but not on B cells or renal cells, which do not express both
receptors. Hence, TLR3 and TLR7 co-activation had no
additive effects on experimental glomerulonephritis.26
Furthermore, viral dsRNA and ssRNA are unable to trigger
the onset of de novo glomerulonephritis.
Not much is yet known about the functional significance
of TLR-independent viral RNA recognition in the kidney.
Immunostaining colocalized RIG-I protein to the mesangial
area of patients with active lupus nephritis and the staining
Table 3 | Innate RNA recognition
TLR-dependent TLR-independent
RNA format dsRNA ssRNA dsRNA, 3P-RNA
Self vs. non-self Methylation (self) Methylation (self) Unmodified 5’-triphosphate motif
Cellular compartment Endosomes Endosomes Cytosol
Receptors TLR3 TLR7, hTLR8 MDA5, RIG-I
Signaling molecules TRIF, TRAF-6, TBK-1, IRF-3, NF-kB MyD88, TRAF-6, IRAK1, IRF-7, NF-kB IPS-1, TBK-1, IRF-3, NF-kB
Cell types Myeloid DCs, non-immune cells like
mesangial cells, endothelial cells
plasmacytoid DCs, B cells, macrophages
(mice)
DCs, B cells, non-immune cells like
fibroblasts, mesangial cells, tubular cells
DCs, dendritic cells; MyD88, myeloid differentiation primary-response protein 88; IRAK-1, interleukin-1 receptor-associated kinase-1; IRF-7, interferon regulatory factor-7;
NF-kB, nuclear factor-kB; 3P-RNA, triphosphate RNA; TBK-1, TANK-binding kinase-1; TLR, toll-like receptor; TRAF-6, tumor necrosis factor receptor associated factor;
TRIF, TIR domain-containing adaptor protein-inducing-interferon-b.
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intensity correlated with disease activity.27 Cultured glomer-
ular endothelial cells, mesangial cells, and tubular epithelial
cells express basal levels of RIG-I and MDA5 and both are
induced upon exposure to proinflammatory cytokines.
Whether exposure to viral 50-triphosphate RNA modulates
lupus nephritis, and if so, via which immune mechanisms
remains to be examined.
Renal infections. Few RNA viruses cause renal pathology by
replicating in renal cells. Human-immunodeficiency virus
although shown to replicate in glomerular cells, but these
cells lack TLR7.19,25 Whether human-immunodeficiency
virus RNA ligates the cytosolic RNA receptors is unknown
to date. However, the diverse clinical pattern of human-
immunodeficiency virus nephropathy may include multiple
other pathomechanisms. Acute renal failure in Hantanvirus
infection is associated with a septic shock-like massive
increase in renovascular permeability, proteinuria, and
intrarenal cytokine expression. Whether this involves viral
recognition via TLR2-4 or the cytosolic RNA receptors in
vascular endothelial cells, podocytes, and tubular epithelial
cells remains to be studied. By contrast, DNA viruses like
cytomegalovirus are known to generate RNA transcripts
activate dendritic cells via TLR3.20 However, the functional
role of intrarenal viral RNA recognition for renal pathology
remains to be studied.
Summary and outlook
The evolving data on innate pathogen recognition receptors
provide novel concepts about how infections can trigger renal
pathology. TLRs, RLHs, and NLRs all activate immune cells
upon recognition of infective organisms. Extrarenal pathogen
recognition can cause renal pathology by systemic cytokine
release or by immune complex formation. Furthermore,
circulating microbial components can activate immune and
non-immune cells in the kidney. Renal non-immune cells
express a restricted pattern of TLRs but the expression
patterns of NLRs and RLHs has not been characterized in
detail. TLRs on, for example, tubular epithelial cells also
mediate innate immune signaling during renal infection, but
whether the intrarenal network of dendritic cells contributes
to pathogen recognition via these receptors has not been
formally demonstrated. The specificity of a few innate
recognition receptors for universal pathogen-associated
molecules is not absolute and they definitely recognize and
trigger danger signals in response to self-molecules. To
elucidate the roles of these receptors for the pathogenesis of
non-infectious kidney diseases and renal infections appears to
be as a promising field for unexpected discoveries in the future.
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